Description
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Product Unit Size | Cost | Quantity | Stock |
---|
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Cas No. | 366017-09-6 |
---|---|
Purity | ≥99% |
Formula | C25H23F3N4O2 |
Formula Wt. | 468.47 |
Chemical Name | 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole |
IUPAC Name | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4- (trifluoromethyl)phenyl]ethenyl]-1,3-oxazole |
Synonym | TAK-165 |
Appearance | White to off white powder |
Store Temp | Ambient |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92. PMID: 16771730.
Triterpene saponin found in species of Panax.
Nucleobase (adenine) analog; DNA polymerase inh...
Benzoquinone ansamycin; topoisomerase VI-B, HSP...
Melatonin analog; MT1/2 agonist, 5-HT2C antagon...
Steroid; glucocorticoid agonist.
Endogenous peptide hormone, somatostatin analog...
Catalyzes hydrolysis of asparagine.
Endogenous peptide, cleavage product of angiote...
principal metabolic product of COX-2
Peptide, GnRH analog.
Pyrimidine nucleoside (cytidine) analog; DNA ch...
Mycotoxin produced by species of Aspergillus; D...
Anthracycline, DNA intercalator; topoisomerase ...
Selective and reversible JAK inhibitor.
RT inhibitor.
ATP competitive CDK inhibitor.
BRG1/BRM ATPase inhibitor
Phytoalexin
Organosulfur found in garlic; Kir K+ channel ac...
FAAH inhibitor.